Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Change in Working Capital Change in Working Capital Deferred Taxes Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Equity Investments Gains from Equity Investments Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Growth Metrics

Cresco Labs (CRLBF) Divestments (2021)

Cresco Labs filings provide 1 years of Divestments readings, the most recent being $69000.0 for Q1 2021.

On a quarterly basis, Divestments changed N/A to $69000.0 in Q1 2021 year-over-year; TTM through Dec 2021 was $69000.0, a N/A change, with the full-year FY2025 number at $350000.0, changed N/A from a year prior.
Divestments hit $69000.0 in Q1 2021 for Cresco Labs.
In the past five years, Divestments ranged from a high of $69000.0 in Q1 2021 to a low of $69000.0 in Q1 2021.